The company said it will initially evaluate different antigens of the parasite that causes malaria over the coming months to help select the multi-antigen vaccine candidate with which to proceed to later-stage trials.
Scientists around the world have been working for decades to develop a vaccine to prevent malaria, which infects millions of people every year and leads to hundreds of thousands of deaths -most of them babies and young children in the poorest parts of Africa. The world’s first and only licensed malaria vaccine, Mosquirix, was developed by GSK Plc over many years of clinical trials across several African countries but is only around 30% effective.
In addition, a lack of funding and commercial potential have thwarted GSK’s capacity to produce as many doses of its shot as needed. MRNA vaccines, which came into the spotlight amid drug makers’ race to develop a vaccine against the coronavirus, prompt the human body to make a protein that is part of the pathogen, triggering an immune response.
From our experience with covid mRNA 'vaccines' I would advise people to stay away from this 'technology', but it is a matter of free choice I guess.
Looks like mRNA is gaining more traction after the success that Moderna labs had
Nigeria Nigeria Latest News, Nigeria Nigeria Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SABCNews - 🏆 37. / 51 Read more »
Source: News24 - 🏆 4. / 80 Read more »